Abstract:Background: Acute hepatic porphyria (AHP) is a group of rare but treatable conditions associated with diagnostic delays of 15 years on average. The advent of electronic health records (EHR) data and machine learning (ML) may improve the timely recognition of rare diseases like AHP. However, prediction models can be difficult to train given the limited case numbers, unstructured EHR data, and selection biases intrinsic to healthcare delivery. We sought to train and characterize models for identifying patients with AHP. Methods: This diagnostic study used structured and notes-based EHR data from 2 centers at the University of California, UCSF (2012-2022) and UCLA (2019-2022). The data were split into 2 cohorts (referral and diagnosis) and used to develop models that predict (1) who will be referred for testing of acute porphyria, among those who presented with abdominal pain (a cardinal symptom of AHP), and (2) who will test positive, among those referred. The referral cohort consisted of 747 patients referred for testing and 99 849 contemporaneous patients who were not. The diagnosis cohort consisted of 72 confirmed AHP cases and 347 patients who tested negative. The case cohort was 81% female and 6-75 years old at the time of diagnosis. Candidate models used a range of architectures. Feature selection was semi-automated and incorporated publicly available data from knowledge graphs. Our primary outcome was the F-score on an outcome-stratified test set. Results: The best center-specific referral models achieved an F-score of 86%-91%. The best diagnosis model achieved an F-score of 92%. To further test our model, we contacted 372 current patients who lack an AHP diagnosis but were predicted by our models as potentially having it (≥10% probability of referral, ≥50% of testing positive). However, we were only able to recruit 10 of these patients for biochemical testing, all of whom were negative. Nonetheless, post hoc evaluations suggested that these models could identify 71% of cases earlier than their diagnosis date, saving 1.2 years. Conclusions: ML can reduce diagnostic delays in AHP and other rare diseases. Robust recruitment strategies and multicenter coordination will be needed to validate these models before they can be deployed.

Advances in the Diagnosis and Treatment of Porphyria-Related Hepatic Manifestations

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

The clinical management of porphyria cutanea tarda: An update

Hepatic Porphyria Accompanied by Neural and Psychic Symptoms

Update review of the acute porphyrias

Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations.

Therapeutic approach to acute crises of hepatic porphyrias

Porphyrin and heme metabolism and the porphyrias

Long‐term complications in acute porphyria

Best practice guidelines on first-line laboratory testing for porphyria

Liver transplantation and primary liver cancer in porphyria

Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias

High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis

A case report of acute intermittent porphyria leading to severe disability

Liver Involvement in Patients with Erythropoietic Protoporphyria: Retrospective Analysis of Clinicopathological Features of 5 Cases

Novel hydroxymethylbilane synthase gene mutation identified and confirmed in a woman with acute intermittent porphyria: A case report

Acute Intermittent Porphyria: A Diagnostic Conundrum

Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria.

Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning

A Novel 55-Basepair Deletion of Hydroxymethylbilane Synthase Gene Found in a Chinese Patient with Acute Intermittent Porphyria and Her Family: A Case Report.

Nontargeted urine metabolomic analysis of acute intermittent porphyria reveals novel interactions between bile acids and heme metabolism: New promising biomarkers for the long‐term management of patients